Ono, R.; Nakayama, K.; Nakamura, K.; Yamashita, H.; Ishibashi, T.; Ishikawa, M.; Minamoto, T.; Razia, S.; Ishikawa, N.; Otsuki, Y.;
et al. Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies). Int. J. Mol. Sci. 2019, 20, 3744.
https://doi.org/10.3390/ijms20153744
AMA Style
Ono R, Nakayama K, Nakamura K, Yamashita H, Ishibashi T, Ishikawa M, Minamoto T, Razia S, Ishikawa N, Otsuki Y,
et al. Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies). International Journal of Molecular Sciences. 2019; 20(15):3744.
https://doi.org/10.3390/ijms20153744
Chicago/Turabian Style
Ono, Ruriko, Kentaro Nakayama, Kohei Nakamura, Hitomi Yamashita, Tomoka Ishibashi, Masako Ishikawa, Toshiko Minamoto, Sultana Razia, Noriyoshi Ishikawa, Yoshiro Otsuki,
and et al. 2019. "Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies)" International Journal of Molecular Sciences 20, no. 15: 3744.
https://doi.org/10.3390/ijms20153744
APA Style
Ono, R., Nakayama, K., Nakamura, K., Yamashita, H., Ishibashi, T., Ishikawa, M., Minamoto, T., Razia, S., Ishikawa, N., Otsuki, Y., Nakayama, S., Onuma, H., Kurioka, H., & Kyo, S.
(2019). Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies). International Journal of Molecular Sciences, 20(15), 3744.
https://doi.org/10.3390/ijms20153744
